

Jens D Lundgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1869606/publications.pdf>

Version: 2024-02-01

471
papers

44,593
citations

4146

87
h-index

2385

198
g-index

478
all docs

478
docs citations

478
times ranked

37795
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	27.0	5,834
2	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , 2015, 373, 795-807.	27.0	2,232
3	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
4	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet</i> , The, 2002, 360, 119-129.	13.7	1,415
5	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.	8.4	1,398
6	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2007, 356, 1723-1735.	27.0	1,393
7	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	7.4	1,076
8	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
9	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet</i> , The, 2008, 371, 1417-1426.	13.7	809
10	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-1193.	2.2	770
11	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet</i> , The, 2014, 384, 241-248.	13.7	767
12	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.. <i>Clinical Infectious Diseases</i> , 2017, 64, 87-91.	5.8	686
13	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet</i> , The, 2019, 393, 2428-2438.	13.7	627
14	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	4.0	575
15	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	2.2	472
16	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454.	2.5	456
17	Current Epidemiology of <i>Pneumocystis</i> Pneumonia. <i>Emerging Infectious Diseases</i> , 2004, 10, 1713-1720.	4.3	387
18	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. <i>Aids</i> , 2010, 24, 1537-1548.	2.2	381

#	ARTICLE	IF	CITATIONS
19	Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	4.0	362
20	SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2005, 42, 615-624.	3.7	357
21	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	27.0	357
22	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	2.2	353
23	Projected life expectancy of people with HIV according to timing of diagnosis. <i>Aids</i> , 2012, 26, 335-343.	2.2	350
24	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	9.1	345
25	Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial*. <i>Critical Care Medicine</i> , 2011, 39, 2048-2058.	0.9	336
26	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950.	2.2	335
27	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-93.	2.2	335
28	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501.	2.8	309
29	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet</i> , The, 2004, 364, 51-62.	13.7	303
30	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
31	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 1359-1369.	4.0	271
32	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
33	Effects of mutations in <i>Pneumocystis carinii</i> dihydropteroate synthase gene on outcome of AIDS-associated <i>P. carinii</i> pneumonia. <i>Lancet</i> , The, 1999, 354, 1347-1351.	13.7	254
34	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 262-270.	2.1	243
35	The role of HIV in serious diseases other than AIDS. <i>Aids</i> , 2008, 22, 2409-2418.	2.2	227
36	Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2001, 183, 1290-1294.	4.0	219

#	ARTICLE	IF	CITATIONS
37	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet, The</i> , 2006, 368, 451-458.	13.7	209
38	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
39	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet, The</i> , 1999, 353, 1293-1298.	13.7	206
40	Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. <i>PLoS ONE</i> , 2013, 8, e55312.	2.5	197
41	Chronic renal failure among HIV-1-infected patients. <i>Aids</i> , 2007, 21, 1119-1127.	2.2	192
42	Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. <i>Journal of Infectious Diseases</i> , 2008, 197, 1145-1155.	4.0	191
43	Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. <i>Antiviral Therapy</i> , 2008, 13, 177-188.	1.0	191
44	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	2.2	188
45	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	6.3	188
46	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223.	1.8	180
47	Prospective Evaluation of a Whole-Blood Test Using <i>Mycobacterium tuberculosis</i> -Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis. <i>Vaccine Journal</i> , 2005, 12, 491-496.	3.1	164
48	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. <i>Lancet, The</i> , 2008, 371, 1443-1451.	13.7	158
49	Predicting risk of cancer during HIV infection. <i>Aids</i> , 2013, 27, 1433-1441.	2.2	158
50	Substance P and Neurokinin A in Human Nasal Mucosa. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1991, 4, 228-236.	2.9	157
51	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. <i>Aids</i> , 2011, 25, 1305-1315.	2.2	157
52	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. <i>Lancet HIV,the</i> , 2016, 3, e23-e32.	4.7	157
53	Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.	27.0	155
54	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV,the</i> , 2018, 5, e291-e300.	4.7	155

#	ARTICLE	IF	CITATIONS
55	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0155100.	2.5	150
56	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	4.0	145
57	Factors Associated With Plasma IL-6 Levels During HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 585-595.	4.0	145
58	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	145
59	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 36-43.	2.1	142
60	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , 2015, 528, S68-S76.	27.8	141
61	Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 200, 973-983.	4.0	140
62	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 68, 1420-1426.	5.8	136
63	Update on <i>Pneumocystis carinii</i> f. sp. <i>hominis</i> Typing Based on Nucleotide Sequence Variations in Internal Transcribed Spacer Regions of rRNA Genes. <i>Journal of Clinical Microbiology</i> , 1998, 36, 734-741.	3.9	133
64	The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. <i>Cancer</i> , 2004, 100, 2644-2654.	4.1	132
65	The Coding Causes of Death in HIV (CoDe) Project. <i>Epidemiology</i> , 2011, 22, 516-523.	2.7	129
66	Pathogenesis of airway mucus hypersecretion. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 85, 399-417.	2.9	123
67	Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1103-1107.	4.0	123
68	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369.	2.1	122
69	Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2002, 137, 239.	3.9	122
70	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. <i>Aids</i> , 1999, 13, 2075-2082.	2.2	121
71	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010, 116, 5306-5315.	4.1	120
72	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119

#	ARTICLE	IF	CITATIONS
73	Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1â€“Infected Patients: The MaxCmin1 Trial. <i>Journal of Infectious Diseases</i> , 2003, 188, 635-642.	4.0	118
74	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 178-187.	4.0	116
75	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.	2.2	109
76	Pneumonia in HIV-infected Persons. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 630-636.	5.6	104
77	Diagnostic Use of PCR for Detection of <i>Pneumocystis carinii</i> in Oral Wash Samples. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2068-2072.	3.9	103
78	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005, 10, 811-823.	1.0	103
79	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , 2013, 10, S5-S36.	1.6	100
80	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , 2016, 14, 61.	5.5	100
81	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751.	2.2	99
82	Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. <i>Antiviral Therapy</i> , 2008, 13, 177-87.	1.0	95
83	Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 408-416.	4.0	94
84	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074.	1.0	92
85	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Postâ€“Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
86	Aging with HIV in Africa. <i>Aids</i> , 2012, 26, S1-S5.	2.2	89
87	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. <i>Aids</i> , 2013, 27, 407-415.	2.2	89
88	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. <i>Circulation</i> , 2009, 119, 805-811.	1.6	88
89	Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. <i>Aids</i> , 1999, 13, 1647-1651.	2.2	86
90	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732.	2.2	85

#	ARTICLE	IF	CITATIONS
91	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2019, 6, e116-e127.	4.7	84
92	Ageing and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416.	2.2	83
93	The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 198-220.	1.9	81
94	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.	2.2	79
95	Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. <i>Aids</i> , 2011, 25, 843-850.	2.2	79
96	Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 016-025.	2.7	79
97	Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. <i>BMJ Open</i> , 2012, 2, e000635.	1.9	77
98	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , 2010, 24, 427-435.	2.2	76
99	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	3.4	75
100	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. <i>Nature Communications</i> , 2020, 11, 363.	12.8	75
101	HIV-associated lymphoma: Histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1416-1423.	0.7	73
102	Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 579-586.	5.8	73
103	Factors Associated with the Development of Opportunistic Infections in HIV-1 Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.	4.0	70
104	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
105	Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. <i>Aids</i> , 2003, 17, 2045-2052.	2.2	69
106	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	2.2	69
107	Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. <i>Aids</i> , 1999, 13, F9-F16.	2.2	69
108	Dexamethasone Inhibits Respiratory Glycoconjugate Secretion from Feline Airways In Vitro by the Induction of Lipocortin (Lipomodulin) Synthesis. <i>The American Review of Respiratory Disease</i> , 1988, 137, 353-357.	2.9	68

#	ARTICLE	IF	CITATIONS
109	When should antiretroviral therapy for HIV be started?. <i>BMJ: British Medical Journal</i> , 2007, 334, 76-78.	2.3	68
110	Cardiovascular implications from untreated human immunodeficiency virus infection. <i>European Heart Journal</i> , 2011, 32, 945-951.	2.2	68
111	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
112	Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2031-2036.	5.8	68
113	Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. <i>PLoS ONE</i> , 2012, 7, e40245.	2.5	66
114	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421.	5.8	66
115	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262.	0.9	65
116	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289.	2.2	64
117	Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S57-S62.	4.0	64
118	Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 14-19.	1.5	63
119	Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. <i>Aids</i> , 2011, 25, 367-377.	2.2	62
120	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.	2.2	62
121	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	2.2	61
122	Prognostic Markers of Short-term Mortality in AIDS-Associated <i>Pneumocystis carinii</i> Pneumonia. <i>Chest</i> , 2001, 119, 844-851.	0.8	61
123	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016, 16, 713.	2.9	61
124	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2018, 5, e146-e154.	4.7	61
125	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. <i>Aids</i> , 2014, 28, 187-199.	2.2	60
126	Factors Associated with D-Dimer Levels in HIV-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e90978.	2.5	60

#	ARTICLE	IF	CITATIONS
127	Frequent hepatitis B virus rebound among HIVâ€“hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
128	Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. <i>Frontiers in Immunology</i> , 2021, 12, 779453.	4.8	59
129	A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. <i>Aids</i> , 1994, 8, 831-836.	2.2	58
130	Inhibition of Leukocyte Entry into the Brain by the Selectin Blocker Fucoidin Decreases Interleukin-1 (IL-1) Levels but Increases IL-8 Levels in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. <i>Infection and Immunity</i> , 2000, 68, 3153-3157.	2.2	58
131	YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis. <i>Vaccine Journal</i> , 2002, 9, 598-604.	3.1	58
132	Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIVâ€“Infected Adults: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2004, 190, 148-155.	4.0	58
133	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160.	0.3	58
134	Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018, 73, 431-438.	5.6	57
135	The CD4 lymphocyte count and risk of clinical progression. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 43-49.	3.8	56
136	Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resourceâ€“Limited Settings. <i>Journal of Infectious Diseases</i> , 2009, 200, 687-697.	4.0	56
137	Prevention of HIV-1 Infection with Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 1934-1935.	27.0	56
138	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
139	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
140	Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. <i>Aids</i> , 2003, 17, 831-840.	2.2	55
141	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802.	1.0	55
142	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. <i>Journal of the International AIDS Society</i> , 2012, 15, 17426.	3.0	54
143	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121.	2.5	54
144	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53

#	ARTICLE	IF	CITATIONS
145	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV</i> , 2016, 3, e120-e131.	4.7	53
146	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197.	4.0	52
147	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. <i>Antiviral Therapy</i> , 2006, 11, 707-716.	1.0	52
148	Changes in use of antiretroviral therapy in regions of Europe over time. <i>Aids</i> , 1998, 12, 2031-2039.	2.2	51
149	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	3.0	51
150	Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748.	2.2	51
151	Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 183-192.	10.7	51
152	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005, 10, 735-743.	1.0	51
153	The natural history of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	3.8	50
154	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral) Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 107-115.	2.2	50
155	Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463.	2.1	49
156	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. <i>Aids</i> , 2015, 29, 1855-1862.	2.2	49
157	Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. <i>BMJ: British Medical Journal</i> , 1995, 311, 1468-1471.	2.3	49
158	Does Cytomegalovirus Predict a Poor Prognosis in Pneumocystis carinii Pneumonia Treated With Corticosteroids?. <i>Chest</i> , 1995, 108, 411-414.	0.8	48
159	Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. <i>Aids</i> , 1996, 10, 911-918.	2.2	48
160	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , 2001, 15, 201-209.	2.2	48
161	Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in <i>Pneumocystis carinii</i> f.sp. <i>hominis</i> . <i>Aids</i> , 2001, 15, 451-459.	2.2	48
162	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	5.8	48

#	ARTICLE	IF	CITATIONS
163	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , The, 2022, 399, 530-540.	13.7	48
164	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i> , the, 2022, 9, e474-e485.	4.7	48
165	Antibody Responses to a Major <i>Pneumocystis carinii</i> Antigen in Human Immunodeficiency Virus-Infected Patients with and without <i>P. carinii</i> Pneumonia. <i>Journal of Infectious Diseases</i> , 1992, 165, 1151-1155.	4.0	47
166	Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. <i>Journal of Electrocardiology</i> , 2011, 44, 779-785.	0.9	47
167	Projected Lifetime Healthcare Costs Associated with HIV Infection. <i>PLoS ONE</i> , 2015, 10, e0125018.	2.5	47
168	Anemia and Survival in Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2003, 37, S297-S303.	5.8	46
169	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 324-333.	2.1	46
170	Liver-related death among HIV/hepatitis C virus-co-infected individuals. <i>Aids</i> , 2015, 29, 1205-1215.	2.2	46
171	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369.	2.1	45
172	Predicted levels of HIV drug resistance. <i>Aids</i> , 2014, 28, S15-S23.	2.2	45
173	Dexamethasone Reduces Rat Tracheal Goblet Cell Hyperplasia Produced by Human Neutrophil Products. <i>Experimental Lung Research</i> , 1988, 14, 853-863.	1.2	44
174	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL : secondary outcome results from a randomised controlled trial. <i>Lancet HIV</i> , the, 2017, 4, e105-e112.	4.7	44
175	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43
176	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
177	Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 582-589.	2.1	42
178	Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879.	5.8	42
179	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. <i>Journal of Infectious Diseases</i> , 2014, 210, 234-243.	4.0	42
180	Late presentation of chronic viral hepatitis for medical care: a consensus definition. <i>BMC Medicine</i> , 2017, 15, 92.	5.5	42

#	ARTICLE	IF	CITATIONS
181	Substance P Receptor-Mediated Secretion of Respiratory Glycoconjugate from Feline Airways in Vitro. <i>Experimental Lung Research</i> , 1989, 15, 17-29.	1.2	41
182	Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 890-901.	1.5	41
183	Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 568-577.	2.1	41
184	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 229-237.	2.1	40
185	Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. <i>Transplantation</i> , 2018, 102, 326-332.	1.0	40
186	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.	2.2	39
187	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , 2011, 25, 1497-1504.	2.2	39
188	Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naïve populations beginning treatment: modelling study and economic analysis. <i>Lancet HIV</i> , 2014, 1, e85-e93.	4.7	39
189	Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients. <i>Critical Care Medicine</i> , 2015, 43, 594-602.	0.9	39
190	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	2.2	38
191	The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. <i>Aids</i> , 2008, 22, 47-56.	2.2	38
192	Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. <i>Journal of Infection</i> , 2014, 68, 259-263.	3.3	38
193	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 579-588.	2.1	38
194	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574.	1.0	38
195	The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. <i>BMC Infectious Diseases</i> , 2008, 8, 91.	2.9	37
196	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008, 22, 2187-2198.	2.2	37
197	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , 2009, 23, 2485-2495.	2.2	36
198	Impact of Human Immunodeficiency Virus-Related Gut Microbiota Alterations on Metabolic Comorbid Conditions. <i>Clinical Infectious Diseases</i> , 2020, 71, e359-e367.	5.8	36

#	ARTICLE	IF	CITATIONS
199	Changing Patterns of Kaposi's Sarcoma in Danish Acquired Immunodeficiency Syndrome Patients with Complete Follow-up. <i>American Journal of Epidemiology</i> , 1995, 141, 652-658.	3.4	35
200	Human Herpes Virus-8 DNA in Bronchoalveolar Lavage Samples from Patients with AIDS-associated Pulmonary Kaposi's Sarcoma. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 13-16.	1.5	35
201	Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. <i>Journal of Neuroimmunology</i> , 2005, 166, 126-131.	2.3	35
202	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	1.0	35
203	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. <i>Aids</i> , 2012, 26, 315-323.	2.2	35
204	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	2.5	35
205	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 ⁺ T-cell Counts. <i>Antiviral Therapy</i> , 2007, 12, 325-334.	1.0	35
206	Attenuation of the Bacterial Load in Blood by Pretreatment with Granulocyte-Colony-Stimulating Factor Protects Rats from Fatal Outcome and Brain Damage during <i>Streptococcus pneumoniae</i> Meningitis. <i>Infection and Immunity</i> , 2004, 72, 4647-4653.	2.2	34
207	Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.	2.2	34
208	Impact of Bacteremia on the Pathogenesis of Experimental Pneumococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2008, 197, 235-244.	4.0	34
209	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1212-1220.	4.0	34
210	Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. <i>Aids</i> , 2019, 33, 675-683.	2.2	34
211	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , 2009, 32, 474-480.	8.6	33
212	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	3.9	33
213	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	2.5	32
214	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752.	6.7	31
215	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e101785.	2.5	31
216	Heterogeneity and Compartmentalization of <i>Pneumocystis carinii</i> f. sp. <i>hominis</i> Genotypes in Autopsy Lungs. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3789-3792.	3.9	30

#	ARTICLE	IF	CITATIONS
217	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. <i>Aids</i> , 2008, 22, 2381-2390.	2.2	30
218	Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. <i>BMC Public Health</i> , 2012, 12, 296.	2.9	30
219	When to start antiretroviral therapy: the need for an evidence base during early HIV infection. <i>BMC Medicine</i> , 2013, 11, 148.	5.5	30
220	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014, 43, 166-177.	6.7	30
221	Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1126-1133.	6.0	30
222	Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV. <i>American Journal of Gastroenterology</i> , 2005, 100, 1446-1454.	0.4	29
223	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. <i>HIV Clinical Trials</i> , 2011, 12, 109-117.	2.0	29
224	Starting highly active antiretroviral therapy: why, when and response to HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 10-13.	3.0	28
225	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV</i> , the, 2018, 5, e172-e180.	4.7	28
226	Contemporary protease inhibitors and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 8-13.	3.1	28
227	In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. <i>BMC Medical Imaging</i> , 2008, 8, 1.	2.7	27
228	Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. <i>Clinical Trials</i> , 2010, 7, 705-718.	1.6	27
229	The cardiovascular risk management for people living with HIV in Europe. <i>Aids</i> , 2016, 30, 2505-2518.	2.2	27
230	Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky053.	2.9	27
231	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , 2004, 18, 1795-1804.	2.2	26
232	The metabolic syndrome in HIV. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 479-486.	4.7	26
233	Why <sc>START</sc>? Reflections that led to the conduct of this large long-term strategic <sc>HIV</sc> trial. <i>HIV Medicine</i> , 2015, 16, 1-9.	2.2	26
234	Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25297.	3.0	26

#	ARTICLE	IF	CITATIONS
235	Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. <i>Leukemia</i> , 2019, 33, 662-670.	7.2	26
236	Amount of <i>Pneumocystis carinii</i> and Degree of Acute Lung Inflammation in HIV-associated <i>P. carinii</i> Pneumonia. <i>Chest</i> , 1993, 104, 109-113.	0.8	25
237	Prognostic Value of Interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1058-1062.	5.6	25
238	Highly active antiretroviral therapy and coronary heart disease: the need for perspective. <i>Aids</i> , 2001, 15, S193-S201.	2.2	25
239	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
240	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	2.2	25
241	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	2.2	25
242	The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. <i>Lancet</i> , The, 2015, 386, 505-507.	13.7	24
243	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	2.2	24
244	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 240-250.	2.1	24
245	Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings. <i>PLoS ONE</i> , 2014, 9, e109148.	2.5	24
246	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , 2003, 8, 127-136.	1.0	24
247	Factors associated with the development of cytomegalovirus infection following solid organ transplantation. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 360-365.	1.5	23
248	Update on HIV in Western Europe. <i>Current HIV/AIDS Reports</i> , 2014, 11, 177-185.	3.1	23
249	Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13252.	1.7	23
250	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288.	2.2	22
251	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , 2007, 36, 1309-1318.	1.9	22
252	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300.	3.1	22

#	ARTICLE	IF	CITATIONS
253	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-790.	1.0	22
254	HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 128-134.	2.1	21
255	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. <i>Aids</i> , 2016, 30, 2659-2663.	2.2	21
256	Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 381-385.	2.1	21
257	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 650-657.	5.8	21
258	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz215.	0.9	21
259	Potential Future Impact of a Partially Effective HIV Vaccine in a Southern African Setting. <i>PLoS ONE</i> , 2014, 9, e107214.	2.5	20
260	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.9	20
261	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. <i>Antiviral Therapy</i> , 2016, 21, 495-506.	1.0	20
262	Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. <i>Cancer Medicine</i> , 2020, 9, 3033-3042.	2.8	20
263	Pretreatment with Granulocyte Colony-Stimulating Factor Attenuates the Inflammatory Response but Not the Bacterial Load in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. <i>Infection and Immunity</i> , 1999, 67, 3430-3436.	2.2	20
264	Tuberculosis among HIV-positive patients across Europe. <i>Aids</i> , 2011, 25, 1505-1513.	2.2	19
265	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	4.0	19
266	HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. <i>BMC Infectious Diseases</i> , 2014, 14, S13.	2.9	19
267	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. <i>PLoS ONE</i> , 2015, 10, e0145380.	2.5	19
268	Neutrophil Chemotactic Activity in Bronchoalveolar Lavage Fluid of Patients with AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 367-371.	1.5	18
269	Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx275.	0.9	18
270	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-naïve Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1325-1334.	4.0	18

#	ARTICLE	IF	CITATIONS
271	Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated <i>Staphylococcus aureus</i> bacteremia (SAB7): study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 250.	1.6	18
272	IgM Response to a Human <i>Pneumocystis carinii</i> Surface Antigen in HIV-infected Patients with Pulmonary Symptoms. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 515-520.	1.5	17
273	Serum Type III Procollagen Peptide in Patients with <i>Pneumocystis carinii</i> Infection. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1558-1562.	2.9	17
274	Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. <i>Shock</i> , 2017, 47, 696-701.	2.1	17
275	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424.	8.4	17
276	Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 405-412.	4.0	17
277	Incidence Rates and Risk Factors of <i>Clostridioides difficile</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz086.	0.9	17
278	A Large-Cohort, Longitudinal Study Determines Precancer Disease Routes across Different Cancer Types. <i>Cancer Research</i> , 2019, 79, 864-872.	0.9	17
279	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362.	4.0	17
280	RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	5.0	17
281	Modelled <i>in vivo</i> HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response. <i>Antiviral Therapy</i> , 2008, 13, 399-408.	1.0	17
282	Changes in Survival Over Time After a First Episode of <i>Pneumocystis carinii</i> Pneumonia for European Patients With Acquired Immunodeficiency Syndrome. <i>Archives of Internal Medicine</i> , 1995, 155, 822.	3.8	16
283	Survival in 2367 Zidovudine-Treated Patients According to Use of Other Nucleoside Analogue Drugs. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 239-244.	0.3	16
284	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	1.0	16
285	Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 41-47.	3.8	16
286	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , 2017, 31, 1261-1270.	2.2	16
287	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx212.	0.9	16
288	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. <i>Current HIV/AIDS Reports</i> , 2018, 15, 162-171.	3.1	16

#	ARTICLE	IF	CITATIONS
289	Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy255.	0.9	16
290	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 579-586.	2.1	16
291	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16
292	The Potential of Antimicrobials to Induce Thrombocytopenia in Critically Ill Patients: Data from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e81477.	2.5	16
293	Toxoplasmosis in Danish AIDS Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 597-600.	1.5	15
294	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097.	1.5	15
295	The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. <i>Aids</i> , 2007, 21, 2033-2042.	2.2	15
296	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , 2018, 32, 985-997.	2.2	15
297	Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , 2018, 32, 79-88.	2.2	15
298	Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , 2018, 52, 1800296.	6.7	15
299	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. <i>EClinicalMedicine</i> , 2019, 13, 91-100.	7.1	15
300	The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results. <i>Central European Journal of Public Health</i> , 2008, 16, 99-105.	1.1	15
301	Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells. <i>Immunopharmacology</i> , 1993, 25, 131-144.	2.0	14
302	Influence of the blood bacterial load on the meningeal inflammatory response in <i>Streptococcus pneumoniae</i> meningitis. <i>BMC Infectious Diseases</i> , 2006, 6, 78.	2.9	14
303	Antibiotics in intensive care: Too little or too much?*. <i>Critical Care Medicine</i> , 2011, 39, 1849-1851.	0.9	14
304	Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring. <i>PLoS ONE</i> , 2012, 7, e42834.	2.5	14
305	HIV Therapies and the Kidney: Some Good, Some Not So Good?. <i>Current HIV/AIDS Reports</i> , 2012, 9, 111-120.	3.1	14
306	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016, 6, 114.	4.6	14

#	ARTICLE	IF	CITATIONS
307	Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564.	1.0	14
308	Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV. <i>Aids</i> , 2019, 33, 2205-2210.	2.2	14
309	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , 2002, 7, 271-281.	1.0	14
310	Incidence of abacavir hypersensitivity reactions in EuroSIDA. <i>Antiviral Therapy</i> , 2008, 13, 687-696.	1.0	14
311	Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. <i>Aids</i> , 2004, 18, 1076-1078.	2.2	13
312	Abacavir and increased risk of myocardial infarction – Authors' reply. <i>Lancet, The</i> , 2008, 372, 804-805.	13.7	13
313	Platelet count kinetics following interruption of antiretroviral treatment. <i>Aids</i> , 2013, 27, 59-68.	2.2	13
314	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 456-463.	2.1	13
315	Mild induced hypothermia: Effects on sepsis-related coagulopathy -results from a randomized controlled trial. <i>Thrombosis Research</i> , 2015, 135, 175-182.	1.7	13
316	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	4.0	13
317	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , 2018, 32, 2807-2819.	2.2	13
318	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. <i>Journal of Infectious Diseases</i> , 2019, 219, 254-263.	4.0	13
319	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm ³ : Findings From the Strategic Timing of Antiretroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 10-17.	2.1	13
320	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019, 33, 2013-2024.	2.2	13
321	Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. <i>International Journal of Infectious Diseases</i> , 2020, 91, 188-195.	3.3	13
322	Preoperative TruCulture® whole blood cytokine response predicts postoperative inflammation in pancreaticoduodenectomy patients – A pilot cohort study. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12930.	2.7	13
323	Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1253-1258.	5.0	12
324	Impact of HIV-1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogue-Based Regimens in Antiretroviral Therapy (ART) – Naive and ART-Experienced Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 1180-1190.	4.0	12

#	ARTICLE	IF	CITATIONS
325	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	1.0	12
326	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	1.0	12
327	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918.	2.2	12
328	HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , 2015, 29, 1379-1389.	2.2	12
329	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	6.3	12
330	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , 2018, 4, e355.	1.6	12
331	Increased Risk of Anemia, Neutropenia, and Thrombocytopenia in People With Human Immunodeficiency Virus and Well-Controlled Viral Replication. <i>Journal of Infectious Diseases</i> , 2019, 220, 1834-1842.	4.0	12
332	Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2019, 221, 419-427.	4.0	12
333	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	12
334	Virological Failure among Patients on Haart from across Europe: Results from the EuroSIDA Study. <i>Antiviral Therapy</i> , 2000, 5, 107-112.	1.0	12
335	Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 339-344.	2.5	11
336	Editorial Commentary: Universal Antiretroviral Therapy for HIV Infection?. <i>Clinical Infectious Diseases</i> , 2013, 57, 888-890.	5.8	11
337	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. <i>Aids</i> , 2014, 28, 577-587.	2.2	11
338	Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1422-1431.	2.3	11
339	Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The CSR FENCE score. <i>International Journal of Cancer</i> , 2020, 146, 321-328.	5.1	11
340	The impact of antiretroviral therapy on AIDS and survival. <i>Journal of HIV Therapy</i> , 2006, 11, 36-8.	0.6	11
341	The Effects of Endorphins on Mucous Glycoprotein Secretion from Feline Airways in Vitro. <i>Experimental Lung Research</i> , 1987, 12, 303-309.	1.2	10
342	Platelet-Activating Factor Stimulates Eicosanoid Production in Cultured Feline Tracheal Explants. <i>Experimental Lung Research</i> , 1991, 17, 1079-1094.	1.2	10

#	ARTICLE	IF	CITATIONS
343	The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression. <i>Antiviral Therapy</i> , 2012, 17, 1291-1300.	1.0	10
344	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	10
345	Determinants of IL-6 levels during HIV infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19482.	3.0	10
346	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014, 15, 51.	1.8	10
347	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596.	2.2	10
348	Associations between HIV-RNA-based indicators and virological and clinical outcomes. <i>Aids</i> , 2016, 30, 1961-1972.	2.2	10
349	Are we successfully managing cardiovascular disease in people living with HIV?. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 594-603.	3.8	10
350	Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018, 21, e25083.	3.0	10
351	Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial. <i>BMC Infectious Diseases</i> , 2019, 19, 573.	2.9	10
352	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 730-739.	5.6	10
353	Evaluation of PCR technique for Diagnosing <i>Pneumocystis carinii</i> Pneumonia in HIV Positive Patients using Oropharyngeal washings.. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 9S-9S.	1.7	9
354	XVI. The <i>Pneumocystis carinii</i> major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 129-134.	2.7	9
355	Biomarkers in HIV disease. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 459-462.	3.8	9
356	Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. <i>BMC Infectious Diseases</i> , 2012, 12, 229.	2.9	9
357	Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. <i>Biomarkers in Medicine</i> , 2014, 8, 1073-1083.	1.4	9
358	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014, 28, 2565-2571.	2.2	9
359	Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. <i>BMC Infectious Diseases</i> , 2019, 19, 708.	2.9	9
360	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3214-3221.	5.8	9

#	ARTICLE	IF	CITATIONS
361	Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir. <i>Journal of Infectious Diseases</i> , 2020, 222, 54-61.	4.0	9
362	Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. <i>Clinical Microbiology and Infection</i> , 2022, 28, 391-397.	6.0	9
363	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. <i>Aids</i> , 2001, 15, 999-1008.	2.2	8
364	Meta-analysis of procalcitonin for sepsis detection. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 499-500.	9.1	8
365	Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. <i>Antiviral Therapy</i> , 2013, 18, 285-7.	1.0	8
366	Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. <i>Journal of the International AIDS Society</i> , 2014, 17, 19505.	3.0	8
367	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , 2016, 30, 1629-1637.	2.2	8
368	Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. <i>Antiviral Therapy</i> , 2016, 21, 529-534.	1.0	8
369	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 1629-1634.	4.0	8
370	Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020, 221, 1973-1977.	4.0	8
371	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	2.2	8
372	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
373	Rapid Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid and Serum Samples by Polymerase Chain Reaction: Correlation of Virus Isolation and Clinical Outcome for Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1997, 24, 878-883.	5.8	7
374	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/?L who were assigned to 7.5 MIU interleukin-2. <i>HIV Medicine</i> , 2007, 8, 112-123.	2.2	7
375	Prevention of HIV transmission by antiretroviral therapy. <i>Lancet HIV</i> , the, 2018, 5, e108-e109.	4.7	7
376	Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188.	2.2	7
377	Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e3733-e3739.	5.8	7
378	Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps. <i>HIV Medicine</i> , 2022, 23, 48-59.	2.2	7

#	ARTICLE	IF	CITATIONS
379	Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. <i>Antiviral Therapy</i> , 2008, 13, 399-407.	1.0	7
380	Predicting recovery from acute kidney injury in critically ill patients: development and validation of a prediction model. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2018, 20, 54-60.	0.1	7
381	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	7
382	The whole-mount method as a technique for measuring experimental changes in airway goblet cell number. <i>Apmis</i> , 1989, 97, 1141-1145.	2.0	6
383	Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challenges. <i>International Journal of Epidemiology</i> , 2004, 34, 130-131.	1.9	6
384	Impact of Coinfection With HIV-1 and GB Virus C in Patients Receiving a Ritonavir-Boosted HAART Regimen: A Substudy to the MaxCmin1 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 378-380.	2.1	6
385	Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. <i>Aids</i> , 2008, 22, 997-998.	2.2	6
386	Uncertainty as to Whether the Use of Antiretroviral Therapy for Persons Recently Infected with HIV Has a Favorable Risk-Benefit Ratio. <i>Clinical Infectious Diseases</i> , 2009, 48, 1162-1162.	5.8	6
387	Procalcitonin monitoring in trauma intensive care patients: How helpful is it?*. <i>Critical Care Medicine</i> , 2009, 37, 2093-2094.	0.9	6
388	Electrocardiographic Spatial QRS-T Angle and Incident Cardiovascular Disease in HIV-Infected Patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] Study). <i>American Journal of Cardiology</i> , 2013, 111, 118-124.	1.6	6
389	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. <i>Epidemiology</i> , 2015, 27, 1.	2.7	6
390	Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017, 31, 1973-1977.	2.2	6
391	Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. <i>Clinical Infectious Diseases</i> , 2018, 67, 341-349.	5.8	6
392	Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452.	4.0	6
393	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 632-637.	4.0	6
394	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , 2021, 35, 193-204.	2.2	6
395	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	4.0	6
396	A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2003, 8, 595-602.	1.0	6

#	ARTICLE	IF	CITATIONS
397	Antibody Responses to <i>Pneumocystis carinii</i> in Hospital Personal with and without Exposure to Patients with <i>P. carinii</i> Pneumonia.. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 10S-10S.	1.7	5
398	System to classify cause of deaths in HIV-positive persons. <i>Aids</i> , 2012, 26, 1835-1836.	2.2	5
399	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , 2014, 14, S18.	2.9	5
400	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	1.0	5
401	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	2.2	5
402	Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. <i>BMC Infectious Diseases</i> , 2018, 18, 191.	2.9	5
403	Cost–effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690.	3.0	5
404	ABO blood types and sepsis mortality. <i>Annals of Intensive Care</i> , 2021, 11, 61.	4.6	5
405	Response to Aviv et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 559-561.	4.0	5
406	Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions. <i>Virus Evolution</i> , 2021, 7, veab055.	4.9	5
407	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 370-376.	3.3	5
408	Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. <i>PLoS ONE</i> , 2011, 6, e25665.	2.5	5
409	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. <i>European Journal of Haematology</i> , 2022, 108, 369-378.	2.2	5
410	Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-90.	1.0	5
411	PAF receptor antagonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 1994, 3, 733-742.	4.1	4
412	Newer Therapies for <i>Pneumocystis carinii</i> Pneumonia. <i>Clinical Pulmonary Medicine</i> , 1996, 3, 304-313.	0.3	4
413	Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 33-37.	3.1	4
414	Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1291-1294.	3.0	4

#	ARTICLE	IF	CITATIONS
415	Procalcitonin in liver transplant patients – yet another stone turned. <i>Critical Care</i> , 2008, 12, 108.	5.8	4
416	Guidelines for managing cardiovascular risk: an evolving area. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 205-206.	3.8	4
417	Use of Risk Equations for Predicting Disease Progression in HIV Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 951-953.	5.8	4
418	Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , 2020, 2020, 1-7.	0.6	4
419	Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab462.	0.9	4
420	Dampening the effect of drug resistance in HIV: a leap forward. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 91-92.	9.1	3
421	Are antiretrovirals enough for people living with HIV?. <i>Lancet</i> , The, 2013, 382, 1466-1467.	13.7	3
422	Antiretroviral therapy recommendations for the global community. <i>Aids</i> , 2014, 28, 939-941.	2.2	3
423	Antiretroviral dose reduction: good for patients and rollout. <i>Lancet</i> , The, 2014, 383, 1442-1443.	13.7	3
424	Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , 2014, 47, 264-271.	0.9	3
425	The Association between Detected drug Resistance Mutations and CD4 ⁺ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116.	1.0	3
426	Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. <i>Aids</i> , 2019, 33, 1385-1390.	2.2	3
427	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 248-257.	2.1	3
428	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770.	1.7	3
429	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
430	Monitoring of antiretroviral therapy in low-resource settings – Authors' reply. <i>Lancet</i> , The, 2008, 372, 289.	13.7	2
431	Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/Åµl in the era of cART. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 908-913.	1.5	2
432	Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. <i>Archives of Internal Medicine</i> , 2009, 169, 904.	3.8	2

#	ARTICLE	IF	CITATIONS
433	“is for everything else, not least for expanding HIV testing in Europe. Bulletin of the World Health Organization, 2012, 90, 634-634.	3.3	2
434	Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 3049-3050.	4.4	2
435	Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication. Scientific Reports, 2021, 11, 4383.	3.3	2
436	XVI. The Pneumocystis carinii major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. FEMS Immunology and Medical Microbiology, 1998, 22, 129-134.	2.7	2
437	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. Aids, 2021, 35, 783-789.	2.2	2
438	Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs. Pharmacoepidemiology and Drug Safety, 2003, 12, 357-359.	1.9	1
439	Corrigendum to “SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS” [Hepatology, 2005, 43, 1098]. Journal of Hepatology, 2005, 43, 1098.	3.7	1
440	Issues in the design of trials comparing management strategies for heavily pretreated patients. Current Opinion in HIV and AIDS, 2006, 1, 476-481.	3.8	1
441	Clinical outcomes in clinical trials of anti-HIV treatment. Future HIV Therapy, 2007, 1, 251-258.	0.4	1
442	The elusive search for an HIV vaccine” And what to do meanwhile. Vaccine, 2008, 26, 6491-6493.	3.8	1
443	Reply to Pascual Pareja et al.. Journal of Infectious Diseases, 2009, 199, 1557-1557.	4.0	1
444	Rescue of Severely Immunocompromised HIV-Positive Persons. Journal of Infectious Diseases, 2010, 202, 1467-1469.	4.0	1
445	Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antiviral Therapy, 2011, 16, 781-785.	1.0	1
446	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. Journal of the International AIDS Society, 2014, 17, 19561.	3.0	1
447	When is the best time to initiate antiretroviral therapy?. Lancet HIV, 2015, 2, e312-e313.	4.7	1
448	Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis. Frontiers in Immunology, 2020, 11, 567856.	4.8	1
449	Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 94-100.	4.0	1
450	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infectious Diseases, 2020, 7, ofaa470.	0.9	1

#	ARTICLE	IF	CITATIONS
451	1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients. Open Forum Infectious Diseases, 2020, 7, S565-S565.	0.9	1
452	1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S567-S568.	0.9	1
453	The Efficacy of Zidovudine Is Time Limited-Reply. JAMA - Journal of the American Medical Association, 1994, 272, 1001.	7.4	0
454	Refinement of prompts for rapid response teams*. Critical Care Medicine, 2012, 40, 2241-2242.	0.9	0
455	602Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. Open Forum Infectious Diseases, 2014, 1, S26-S26.	0.9	0
456	Novel Biomarkers of Infection in Critically Ill Cancer Patients. Critical Care Medicine, 2014, 42, 2632-2633.	0.9	0
457	People with HIV are at increased risk of acute myocardial infarction. Evidence-based Nursing, 2014, 17, 43-44.	0.2	0
458	Thrombocytopenia and cancer risk during HIV infection. Aids, 2015, 29, 1425-1427.	2.2	0
459	Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure. Open Forum Infectious Diseases, 2017, 4, S30-S30.	0.9	0
460	Quantification of sexual HIV transmission risk in Africa. International Journal of Infectious Diseases, 2018, 66, 135-136.	3.3	0
461	Language used to convey HIV infection risk is important – Authors' reply. Lancet HIV, the, 2018, 5, e272.	4.7	0
462	2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. Open Forum Infectious Diseases, 2019, 6, S892-S893.	0.9	0
463	2613. The Epidemiology of Respiratory Syncytial Virus (RSV) in People with Immune Dysfunction Seen at a Tertiary Hospital Between 2010 and 2017. Open Forum Infectious Diseases, 2019, 6, S908-S909.	0.9	0
464	2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study. Open Forum Infectious Diseases, 2019, 6, S936-S936.	0.9	0
465	Causes and outcomes of hospitalizations among people living with HIV in Georgia – referral institution, 2012 – 2017. International Journal of STD and AIDS, 2021, 32, 662-670.	1.1	0
466	EuroSIDA: a prospective observational study of chronic HIV infection across the European continent. , 2008, , 195-212.		0
467	ART Failure and Strategies for Switching ART Regimens in Europe. Central European Journal of Public Health, 2008, 16, 141-144.	1.1	0
468	Neuropeptides and Airway Macromolecule Secretion. , 2017, , 447-464.		0

#	ARTICLE	IF	CITATIONS
469	252. Increased incidence rates of positive blood cultures shortly after chemotherapy treatment initiation among individuals treated for solid malignant tumours. Open Forum Infectious Diseases, 2020, 7, S125-S126.	0.9	0
470	29. Sustained Recovery in Patients Admitted to Hospital With COVID-19. Open Forum Infectious Diseases, 2021, 8, S20-S21.	0.9	0
471	23. Development and Validation of a Risk Score for Post-transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, S15-S16.	0.9	0